Legal & General Group PLC Amylyx Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.71 - $19.57 $18,460 - $133,310	-6,812 Reduced 17.17%	32,854 $93,000
Q4 2023 Feb 15, 2024	BUY	$12.07 - $18.46 $91,297 - $139,631	7,564 Added 23.56%	39,666 $583,000
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $64,834 - $84,091	3,586 Added 12.58%	32,102 $587,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $30,714 - $45,998	1,464 Added 5.41%	28,516 $615,000
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $610,423 - $901,646	22,029 Added 438.56%	27,052 $793,000
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $46,469 - $61,324	1,562 Added 45.13%	5,023 $185,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $38,364 - $69,168	2,237 Added 182.76%	3,461 $97,000
Q2 2022 Aug 22, 2022	BUY	$6.85 - $19.93 $2,185 - $6,357	319 Added 35.25%	1,224 $24,000
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $11,629 - $29,774	905 New	905 $12,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.